Physician profile
Larry Flowers
NPI 1750336707
$6,085.98
in general payments reported to CMS, 2019-2025
25 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,418 · 2020: $765 · 2021: $784 · 2022: $403 · 2023: $599 · 2024: $595 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,715.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,012.29 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $979.38 | 2019-2025 | Invega Trinza, Invega Sustenna, Invega |
| Alkermes, INC. | $637.73 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $637.25 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $467.23 | 2019-2022 | |
| Abbvie INC. | $409.02 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $258.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $249.60 | 2025 | Cobenfy |
| Lundbeck LLC | $245.99 | 2019-2024 | Abilify Asimtufii, Rexulti |
| Vanda Pharmaceuticals INC. | $240.80 | 2019-2022 | |
| Allergan, INC. | $238.28 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.19 | 2021-2025 | Caplyta |
| Indivior INC. | $153.58 | 2019-2024 | Sublocade, Perseris |
| Acadia Pharmaceuticals INC | $130.80 | 2023 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $45.63 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $27.01 | 2019 | |
| Harmony Biosciences LLC | $26.15 | 2025 | |
| Supernus Pharmaceuticals, INC. | $24.18 | 2024 | Qelbree |
| Validus Pharmaceuticals LLC | $23.03 | 2025 | Raldesy |
| Eisai INC. | $22.24 | 2021 | |
| Ironshore Pharmaceuticals INC. | $19.42 | 2019 | |
| Avanir Pharmaceuticals, INC. | $18.79 | 2019 | |
| Merck Sharp & Dohme LLC | $18.20 | 2020 | |
| Adlon Therapeutics L.P. | $13.83 | 2020 | |
| Axsome Therapeutics, INC. | $12.60 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Flowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.